A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.
As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.

开始日期2020-06-26

申办/合作机构

Merck Sharp & Dohme Corp.

NCT03516981

/ Active, not recruiting临床2期

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.

开始日期2018-10-01

申办/合作机构

Merck Sharp & Dohme Corp.

NCT03179436

/ Completed临床1/2期

A Phase 1 / 2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

开始日期2017-07-02

申办/合作机构

Merck Sharp & Dohme Corp.

100 项与 Quavonlimab 相关的临床结果

登录后查看更多信息

100 项与 Quavonlimab 相关的转化医学

登录后查看更多信息

100 项与 Quavonlimab 相关的专利（医药）

登录后查看更多信息

项与 Quavonlimab 相关的文献（医药）

2023-12-01·Future oncology (London, England)

LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma

Review

作者: Powles, Thomas ; Perini, Rodolfo F ; Rini, Brian I ; Voss, Martin H ; Gurney, Howard ; Rodriguez-Lopez, Karla ; Song, Yue ; Plimack, Elizabeth R ; Choueiri, Toni K

Combination treatment with immunotherapy agents and/or vascular endothelial growth factor tyrosine kinase inhibitors are a standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). Novel therapeutic combinations that include the hypoxia-inducible factor 2α inhibitor belzutifan and the cytotoxic T-lymphocyte-associated protein 4 inhibitor quavonlimab are being investigated for their potential to further improve patient outcomes. This protocol describes the rationale and design of the randomized, phase III LITESPARK-012 study, which will evaluate the efficacy and safety of pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab as first-line treatment for advanced ccRCC. Results from this study may support triplet combination therapies as a potential new standard of care for advanced ccRCC. Clinical trial registry: NCT04736706 (ClinicalTrials.gov).

2023-07-01·Nature medicine1区 · 医学

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

1区 · 医学

Article

作者: Snyder, Alexandra ; Yuan, Jianda ; Gutierrez, Martin ; Palcza, John ; Luft, Alexander ; Kobie, Julie ; Felip, Enriqueta ; Tan, Daniel Shao Weng ; Hellmann, Matthew D ; Cristescu, Razvan ; Landers, Gregory A ; Basso, Andrea ; Herbst, Roy S ; Ahn, Myung-Ju ; Gubens, Matthew A ; Ma, Hua ; Lee, Jong-Seok ; Finocchiaro, Giovanna ; Lam, Wei-Sen ; Chiu, Joanne W Y ; Fong, Lawrence ; Aggarwal, Charu ; Garon, Edward B ; Yang, James Chih-Hsin

Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively randomized phase 2 study investigating first-line pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily), anti-CTLA-4 quavonlimab (25 mg every 6 weeks) or anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks) in advanced NSCLC. Patients were categorized by T-cell-inflamed gene expression profile (Tcell_infGEP) and tumor mutational burden (TMB) status and randomly assigned 1:1:1 to receive pembrolizumab + lenvatinib, pembrolizumab + quavonlimab or pembrolizumab + favezelimab. The primary outcome was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 using pre-specified efficacy thresholds for each biomarker-defined subgroup (>5% (Tcell_infGEP^lowTMB^non-high (group I)), >20% (Tcell_infGEP^lowTMB^high (group II) and Tcell_infGEP^non-lowTMB^non-high (group III)) and >45% (Tcell_infGEP^non-lowTMB^high (group IV))). Secondary outcomes were progression-free survival, overall survival and safety. At data cutoff, ORR ranges were 0-12.0% in group I, 27.3-33.3% in group II, 13.6-40.9% in group III and 50.0-60.0% in group IV. ORR with pembrolizumab + lenvatinib in group III met the pre-specified efficacy threshold. The safety profile of each treatment arm was consistent with the known safety profile of each combination. These data demonstrate the feasibility of prospective Tcell_infGEP and TMB assessment to study the clinical activity of first-line pembrolizumab-based combination therapies in advanced NSCLC. ClinicalTrials.gov registration: NCT03516981 .

2021-09-01·LUNG CANCER2区 · 医学

Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

2区 · 医学

Article

作者: Yixin Ren ; Myung-Ju Ahn ; Dusan Kotasek ; Dong-Wan Kim ; Shabana Siddiqi ; Drew Rasco ; Ruth Perets ; Adnan Nagrial ; Dae Ho Lee ; Martin Gutierrez ; Jair Bar ; Byoung Chul Cho ; David R. Spigel ; Rachel A. Altura ; Kiyotaka Yoh ; Jiaxin Niu ; Corinne Maurice-Dror ; Miyako Satouchi

OBJECTIVES:

This first-in-human phase I study (NCT03179436) investigated anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody quavonlimab and anti-programmed death 1 monoclonal antibody pembrolizumab in patients with advanced solid tumors. The study was conducted in two parts: dose-escalation (part 1) and dose-confirmation (part 2). First-line treatment with quavonlimab + pembrolizumab conferred encouraging antitumor activity (objective response rate [ORR], 28%-40%) and was generally well tolerated (grade ≥ 3 treatment-related adverse events [TRAEs] were lowest with quavonlimab 25 mg every 6 weeks [Q6W] at 30% and highest with quavonlimab 75 mg Q3W at 57%) in non-small cell lung cancer. We present data from patients with extensive-stage small cell lung cancer (SCLC) receiving second-line or later therapy.

MATERIALS AND METHODS:

Patients with stage III/IV SCLC received quavonlimab 75 mg Q6W plus pembrolizumab 200 mg Q3W for ≤ 2 years. Primary endpoints were safety and tolerability; ORRs as assessed by blinded independent central review per Response Evaluation Criteria In Solid Tumorsv1.1 was a secondary endpoint. Progression-free survival (PFS), overall survival (OS), and the correlation of response with PD-L1 expression were exploratory endpoints.

RESULTS:

Forty patients with extensive-stage SCLC received treatment; median follow-up was 13 months. Dose-limiting toxicity occurred in 4 patients (10%). TRAEs occurred in 80% of patients; grade 3 events occurred in 33% of patients and no grade 4/5 events were reported. Confirmed ORRs (95% CI) were 18% (7-33) among all patients, 7% (<1-34) for PD-L1-positive tumors (n = 14), and 19% (5-42) for PD-L1-negative tumors (n = 21). Response duration ranged from 2.9 to 19.1+ months. Median PFS was 2.0 months; 6-month PFS rate was 26%. Median OS was 11.0 months; 6-month OS rate was 66%.

CONCLUSIONS:

Encouraging antitumor activity was observed with quavonlimab + pembrolizumab in patients with extensive-stage SCLC; responses were observed in PD-L1-positive and PD-L1-negative tumors. The combination was tolerable with manageable toxicities.

项与 Quavonlimab 相关的新闻（医药）

2025-01-22

·PRNewswire

Akeso Received Payment for the Development Collaboration on Tagitanlimab

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclonal antibody targeting PD-L1, following its recent marketing approval by China's National Medical Products Administration. In 2014, Akeso signed a cooperation agreement with Sichuan Kelun for the development of tagitanlimab. Under the terms of the agreement, Akeso will receive royalties from the commercial sales of tagitanlimab in addition to the development payment. Tagitanlimab marks Akeso's second oncology product to yield commercial royalties, following pucotenlimab, a PD-1 monoclonal antibody developed in collaboration with Lepu Biopharma in 2016. Dr. Yu Xia, founder, chairwoman, president, and CEO of Akeso, said: "Congratulations to our partners. We are thrilled about continuously successful approval of our innovative products, and truly anticipate their outstanding commercialization performance. This achievement highlights Akeso's strong R&D capabilities and our commitment to innovation. Since its inception, Akeso has established multiple external collaborations, including ivonescimab with Summit Therapeutics, quavonlimab with Merck and pucotenlimab with Lepu Biopharma. These partnerships not only benefit patients but also deliver significant returns for both Akeso and our collaborators. Looking ahead, Akeso will continue to pursue a diversified strategy for new drug development, leveraging global resources to drive the high-quality commercialization of our independently developed innovative therapeutics." SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出上市批准

2025-01-22

·康方生物Akeso

康方生物收到塔戈利单抗新药合作开发付款

2025年1月22日，康方生物（9926.HK）宣布，因靶向程序性细胞死亡配体1（PD-L1）的创新人源化单克隆抗体塔戈利单抗近日获得中国国家药品监督管理局批准上市，公司已于近日收到四川科伦药物研究院有限公司支付的相应新药合作开发付款。 2014年，康方生物就塔戈利单抗与四川科伦药物研究院有限公司达成相关合作合同，按该合同约定，公司除了因新药开发应取得的付款外，在塔戈利单抗获批上市后，康方生物未来还将持续收到塔戈利单抗商业化销售相应比例的提成。塔戈利单抗也将是康方生物第二个获得商业化销售提成的新药产品。康方生物首个获得商业化销售提成的新药产品为普特利单抗（PD-1单抗），2016年，康方生物与乐普生物科技股份有限公司就康方生物研发的普特利单抗达成相关合作协议。康方生物创始人、董事长、总裁兼首席执行官夏瑜博士表示：非常欣喜地看到康方生物研发的一个又一个新药产品成功实现获批上市，祝贺我们的合作伙伴，期待这些产品能够获得优异的市场表现！不同产品经由不同企业去主导临床开发，但全都取得了成功上市的结果，彰显了康方生物优秀的创新药物自主研发能力。自成立以来，我们已经推动了依沃西（ ivonescimab，PD-1/VEGF双抗）与Summit Therapeutics，Quavonlimab（AK107或MK-1308，CTLA-4单抗）与默沙东，塔戈利单抗（PD-L1单抗）与四川科伦、普特利单抗（PD-1单抗）与乐普生物等一系列产品的对外合作，随着这些产品的成功上市，不仅将造福广大患者，合作伙伴和康方生物也将持续获得相应的研发回报。未来，公司仍将继续推进多元化的新药开发策略，包括但不限于自主开发和对外权益许可等方式，集聚全球优势资源，推动自主研发新药在世界范围内的高质量发展。关于康方生物康方生物（9926.HK）是一家集研究、开发、生产及商业化全球首创或同类最佳创新生物新药于一体的领先企业。自2012年成立以来，公司打造了独有的端对端康方全方位新药研究开发平台（ACE Platform），建立了以Tetrabody双特异性抗体开发技术、抗体偶联（ADC）技术、mRNA技术及细胞治疗技术为核心的研发创新体系，国际化标准的GMP生产体系和运作模式先进的商业化体系，成为了在全球范围内具有竞争力的生物医药创新公司。公司已开发了50个以上用于治疗肿瘤、自身免疫、炎症、代谢疾病等重大疾病的创新候选药物，22个候选药已进入临床（包括11个双抗/多抗/双抗ADC），6个新药已在商业化销售，4个新药6个适应症的上市申请处于审评审批阶段，2个全球首创创新药纳入国家医保目录。 2021年8月，公司自主研发的差异化PD-1单抗安尼可®获批上市；2022年6月，公司全球首创的PD-1/CTLA-4双抗开坦尼®获批上市，成为全球首个获批的肿瘤免疫治疗双抗新药，也是中国第一个双特异性抗体新药。2024年上半年，开坦尼®一线治疗晚期宫颈癌的新药上市许可申请（sNDA）已受理，开坦尼®联合方案一线治疗晚期胃癌适应症于同年9月获批上市。2024年5月，公司另一全球首创双抗新药依达方®获得中国国家药品监督管理局批准上市，用于EGFR-TKI治疗进展的局部晚期或转移性nsq-NSCLC，依达方®成为全球首个获批的“肿瘤免疫+抗血管生成”机制双抗新药。同期，依沃西对比帕博利珠单抗一线治疗PD-L1阳性NSCLC获显著阳性结果，同适应症的sNDA获CDE受理，并获优先审评。依沃西成为全球迄今唯一在头对头III期临床研究中证明疗效显著优于“药王”帕博利珠单抗的药物，将有望成为一线肺癌治疗新的标准治疗方案，为患者提供全新更优的“去化疗”选择。此前，2022年12月，公司对外许可了依达方®部分海外权益，并以50亿美金+销售提成的合作方案创下了彼时中国单药对外许可的最高交易金额纪录。2024年9月，公司自主研发的伊喜宁®（伊努西单抗，PCSK9）治疗高胆固醇血症两项适应症获批，成为非肿瘤领域的首个获批产品。目前，开坦尼®、依达方®均已被纳入2024年国家医保目录。康方生物期望通过高效及突破性的研发创新，开发国际首创及同类药物最佳疗法的新药，成为全球领先的生物制药企业。往期推荐产品动态康方生物卡度尼利、依沃西纳入2024年国家医保目录临床进展头对头度伐利尤单抗方案，依沃西方案一线治疗胆道肿瘤III期临床完成首例患者入组临床进展全球首个CD47单抗实体瘤III期临床首例入组：依沃西联合莱法利一线治疗HNSCC（对比帕博利珠单抗）数据发布卡度尼利一线宫颈癌III期研究成果荣登《Nature Reviews Clinical Oncology》（影响因子高81.1）数据发布 IGCS 2024 LBA & 《柳叶刀》主刊，卡度尼利1L宫颈癌III期研究PFS和OS双阳性结果重磅发布产品动态一线胃癌全人群获批！康方生物卡度尼利获批第二个适应症产品动态获FDA快速通道资格！依沃西国际多中心III期研究HARMONi完成入组，2L+EGFRm NSCLC 数据发布全球首个对比帕博利珠单抗取得显著阳性结果的随机对照大III期研究——依沃西HARMONi-2重磅研究成果在WCLC发表临床进展康方生物卡度尼利联合方案治疗uHCC的III期临床研究完成首例患者入组临床进展针对PD-1/L1治疗进展晚期胃癌，卡度尼利+普络西（VEGFR-2）联合疗法Ⅲ期临床完成首例入组产品动态依沃西1L治疗PD-L1阳性NSCLC的sNDA获NMPA受理，肺癌一线将迎“去化疗”新标准方案！数据发布 ASCO Oral & JAMA主刊丨Ⅲ期HARMONi-A研究重磅公布，依沃西疗法有望改变EGFR-TKI进展肺癌全球治疗标准临床进展史无前例！康方依沃西单药对比帕博利珠1L治疗PD-L1阳性NSCLC的III期临床获决定性胜出阳性结果产品动态康方生物双抗卡度尼利一线治疗晚期宫颈癌全人群的sNDA获CDE受理临床进展国际多中心注册性III期研究HARMONi-3中国启动：依沃西单抗联合化疗对比帕博利珠单抗联合化疗1L治疗sq-NSCLC 临床进展卡度尼利联合化疗对比替雷利珠联合化疗1L治疗PD-L1表达阴性NSCLC的III期临床首例入组产品动态高达50亿美金！康方生物与Summit就PD-1/VEGF双抗依沃西达成合作和许可协议产品动态全球首个肿瘤免疫治疗双抗——开坦尼®（PD-1/CTLA-4双抗，卡度尼利）获批上市

引进/卖出上市批准医药出海细胞疗法抗体药物偶联物

2024-05-23

·BioPharmaDive

ASCO24: An early look at cancer drug study results

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a line!Today, were interrupting our usual rundown of industry news to highlight notable clinical trial updates ahead of next weeks American Society of Clinical Oncologys annual meeting. On Thursday, conference organizers released abstracts, or snapshots, of most of the studies set to be presented at the meeting, which will be held in Chicago from May 31 to June 4.Note: So-called late-breaking abstracts, which often feature particularly consequential trial findings, arent available until the day the relevant studies are presented. This year, that group includes anticipated data on Novartis therapy Scemblix in leukemia, GSKs Blenrep in multiple myeloma and AstraZeneca and Daiichi Sankyos Enhertu treatment in breast cancer.Abstract #9507: Analysts have closely tracked a dual-targeting antibody drug that Immunocore is developing for a type of skin cancer called cutaneous melanoma. Trial results included in an ASCO abstract showed that, among 31 evaluable people who previously received immunotherapy, Immunocores drug led to partial tumor responses in four, or 13%. Including study participants whose disease was considered stable, the so-called clinical benefit rate was 61%. Though slightly below analysts expectations, the data are roughly similar to the results for Bristol Myers Squibbs Odualag in a comparable patient population. Immuncore recently began a Phase 3 trial of its drug, called brenetafusp. Ned PagliaruloAbstracts #5502, 9506: Drugmakers have hoped that targeting an immune cell protein called TIGIT could build on the success seen with checkpoint inhibitors like Merck & Co.s Keytruda and Bristol Myers Squibbs Opdivo. But trial results to date have been mixed and new data included in ASCO abstracts Thursday probably wont settle any debates. On one hand, Phase 2 trial findings for Mercks TIGIT-targeting drug vibostolimab coformulated with Keytruda shrank or eliminated tumors in a larger share of women with a type of endometrial cancer than Keytruda alone. On the other, data from a Phase 1/2 trial of Keytruda, vibostolimab and a third experimental immunotherapy called quavonlimab in advanced melanoma patients werent good enough for the Merck to continue enrolling patients. Jonathan GardnerAbstract #3508: An experimental cocktail of six drugs substantially extended survival and delayed tumor growth, compared to a standard therapy, in people with previously treated metastatic colon cancer, according to an ASCO abstract. The regimen includes two drugs developed by Arcus Biosciences: etrumadenant, a so-called adenosine receptor antagonist, and zimberelimab, a checkpoint inhibitor. Median overall survival among the 75 patients randomized to the cocktail was 19.7 months, versus 9.5 months for the 37 given Stivarga in the Phase 1b/2 study. Arcus is closely partnered with Gilead Sciences, although their focus has been on developing zimberelimab and another immunotherapy. Ned PagliaruloAbstract #5010: Johnson & Johnson is one of many companies now exploring radiopharmaceuticals, which deliver radiation directly to a tumor. Its first chance to break into the field could be JNJ-6420, a drug that executives already billed as a potential future blockbuster. J&J aims to show the drug can slow tumor progression in men whose prostate cancer has progressed after hormone therapies. Early-stage study results disclosed in an abstract show the company may need to manage safety concerns. While 46% of men treated with a select drug dose had a 50% decrease in a marker associated with improved survival, 61% experienced an adverse event graded as severe or medically significant. Four of the 67 patients who received J&Js drug overall in the study died from adverse events. Jonathan GardnerAbstract #6502: Anyone looking for updated trial results on MorphoSys myelofibrosis drug pelabresib will have to wait for ASCO itself, as an abstract for the biotechnology companys MANIFEST-2 study only includes previously presented data. The drug is at the center of Novartis pending $2.9 billion acquisition of MorphoSys, but there are questions about its safety after a Stat report highlighted multiple cases of acute myeloid leukemia developing in pelabresib-treated patients. Ned Pagliarulo '

临床结果ASCO会议并购临床2期免疫疗法

100 项与 Quavonlimab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16422

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾细胞癌	临床3期	-	中山康方生物医药有限公司	-
黑色素瘤	临床2期	美国	Merck GmbH	2020-06-09
非小细胞肺癌	临床2期	美国	Merck GmbH	2020-01-22
晚期恶性实体瘤	临床2期	美国	Merck Sharp & Dohme Corp.	2017-07-02
晚期恶性实体瘤	临床2期	中国	Merck Sharp & Dohme Corp.	2017-07-02
晚期恶性实体瘤	临床2期	日本	Merck Sharp & Dohme Corp.	2017-07-02
晚期恶性实体瘤	临床2期	澳大利亚	Merck Sharp & Dohme Corp.	2017-07-02
晚期恶性实体瘤	临床2期	加拿大	Merck Sharp & Dohme Corp.	2017-07-02
晚期恶性实体瘤	临床2期	智利	Merck Sharp & Dohme Corp.	2017-07-02
晚期恶性实体瘤	临床2期	法国	Merck Sharp & Dohme Corp.	2017-07-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03179436 (MK-1308-001 \| 1308-001, AACR2022) 人工标引	临床1/2期	局部晚期黑色素瘤	151	quavonlimab+pembrolizumab	夢衊顧襯憲鹽艱構鑰築(鹽觸網構蓋鏇醖襯壓窪) = 網艱築衊構範衊鑰窪繭遞膚襯製蓋範網觸鏇簾 (網淵壓構遞繭艱鬱淵餘, 4.4 ~ 15.9) 更多	积极	2022-06-15
NCT03179436 (MK-1308-001 \| 1308-001, AACR2022) 人工标引	临床1/2期	局部晚期黑色素瘤	151	quavonlimab	夢衊顧襯憲鹽艱構鑰築(鹽觸網構蓋鏇醖襯壓窪) = 淵觸齋憲築窪選窪簾積遞膚襯製蓋範網觸鏇簾 (網淵壓構遞繭艱鬱淵餘, 0.1 ~ 13.2) 更多	积极	2022-06-15
NCT03179436 (MK-1308-001 \| 1308-001, Pubmed \| Lung Cancer) 人工标引	临床1/2期	广泛期小细胞肺癌二线	40	quavonlimab+pembrolizumab	製鬱夢蓋顧範膚顧襯壓(夢顧構衊簾齋製餘鏇觸) = 觸膚鹹廠蓋觸齋選獵衊蓋遞觸簾鬱齋衊憲餘蓋 (遞鑰齋膚鑰壓網範襯憲 ) 更多	积极	2021-09-01
NCT03179436 (MK-1308-001 \| 1308-001, ASCO2019)	临床1期	非小细胞肺癌一线	213	MK-1308 plus pembrolizumab	範願廠鹽齋齋構廠繭顧(糧衊襯鑰醖齋鑰簾窪築) = 積獵餘鬱選製蓋積襯蓋廠夢築衊餘繭壓鏇窪製 (遞餘齋衊艱淵壓鬱鬱構 ) 更多	积极	2019-05-26